FDA-cleared profile

DenSeeMammo

Statlife · Mammography/DBT · FDA-cleared (510(k))

Authorized purpose: Adjunctive estimation of the BI-RADS 5th Edition breast-density category from processed digital 2D mammograms to aid radiologists; not diagnostic.

Clinical role
Automated post-processing breast-density assessment and quantitative-reporting support with physician review.
Images and patients
Mammography/DBT · Breast
Key limitation
Keep in mind: The output is adjunctive and not a diagnostic aid; an MQSA-qualified physician makes the final category. The labeled compatibility is limited to the identified FFDM systems and view configurations. Core software was built and tested on OS X, the GUI on Windows/OS X/Linux, the user computer must share a local network with the server, and a web browser is required.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Adjunctive estimation of the BI-RADS 5th Edition breast-density category from processed digital 2D mammograms to aid radiologists; not diagnostic.
  • Which images or clinical context are in scope?Modality: Mammography/DBT Anatomy or clinical context: Breast Input: Processed digital 2D mammograms from FFDM systems, with images extracted from DICOM files; the packet identifies GE Senographe Essentials and Hologic Selenia Dimension systems and supports CC/MLO pairs or specified single-view inputs.
  • Who uses it?Intended users: Radiologists; the final breast-density assessment is made by an MQSA-qualified interpreting physician
  • What does the software produce?Output: A BI-RADS breast-density 5th Edition category is produced for each breast and for each patient, with the patient result based on the maximum category of the two breasts; the browser interface can display the assessment and similar images.
  • What is its most important limitation?Key limitation: The output is adjunctive and not a diagnostic aid; an MQSA-qualified physician makes the final category. The labeled compatibility is limited to the identified FFDM systems and view configurations. Core software was built and tested on OS X, the GUI on Windows/OS X/Linux, the user computer must share a local network with the server, and a web browser is required.

Clinical takeaway. Clinical role: Adjunctive estimation of the BI-RADS 5th Edition breast-density category from processed digital 2D mammograms to aid radiologists; not diagnostic.

Evidence takeaway. Evidence from the reviewed source record: FDA verification and validation covered reproducibility, comparison of left/right and patient-level density results with visual assessments by MQSA-qualified radiologists, GE and Hologic datasets, two-view and single-view configurations, and beta-site testing for physician integration and usability. The packet states that all test acceptance criteria were met; it does not report a device-level sensitivity, specificity, or AUC endpoint.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Adjunctive estimation of the BI-RADS 5th Edition breast-density category from processed digital 2D mammograms to aid radiologists; not diagnostic.
  • Exact FDA submission
  • Checked 2026-09-09
Workflow role
Automated post-processing breast-density assessment and quantitative-reporting support with physician review.
  • Exact FDA submission
  • Checked 2026-09-09
Required input
Processed digital 2D mammograms from FFDM systems, with images extracted from DICOM files; the packet identifies GE Senographe Essentials and Hologic Selenia Dimension systems and supports CC/MLO pairs or specified single-view inputs.
  • Exact FDA submission
  • Checked 2026-09-09
Output and clinician action
A BI-RADS breast-density 5th Edition category is produced for each breast and for each patient, with the patient result based on the maximum category of the two breasts; the browser interface can display the assessment and similar images.
  • Exact FDA submission
  • Checked 2026-09-09
Care setting
Women whose processed digital 2D mammograms from Full Field Digital Mammography systems are analyzed to estimate BI-RADS breast density category; the FDA document does not specify a facility type.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "DenSeeMammo is a software that aims at assessing the breast density of a woman." … "DenSeeMammo is a software application intended for use with Full Field Digital Mammography systems. DenSeeMammo estimates BI-RADS breast density category by analyzing processed digital 2D mammograms using a fully automated comparison procedure.". Read from the exact FDA decision document on 2026-11-14.

Intended users
Radiologists; the final breast-density assessment is made by an MQSA-qualified interpreting physician
  • Exact FDA submission
  • Checked 2026-09-09
Limitations
The output is adjunctive and not a diagnostic aid; an MQSA-qualified physician makes the final category. The labeled compatibility is limited to the identified FFDM systems and view configurations. Core software was built and tested on OS X, the GUI on Windows/OS X/Linux, the user computer must share a local network with the server, and a web browser is required.
  • Exact FDA submission
  • Checked 2026-09-09
Evidence summary
FDA verification and validation covered reproducibility, comparison of left/right and patient-level density results with visual assessments by MQSA-qualified radiologists, GE and Hologic datasets, two-view and single-view configurations, and beta-site testing for physician integration and usability. The packet states that all test acceptance criteria were met; it does not report a device-level sensitivity, specificity, or AUC endpoint.
  • Exact FDA submission
  • Checked 2026-09-09

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA verification and validation covered reproducibility, comparison of left/right and patient-level density results with visual assessments by MQSA-qualified radiologists, GE and Hologic datasets, two-view and single-view configurations, and beta-site testing for physician integration and usability. The packet states that all test acceptance criteria were met; it does not report a device-level sensitivity, specificity, or AUC endpoint.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

DenSeeMammo regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationPopulation described in the exact-submission ACR model card
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K173574
  • IndependenceIndependence not established

K173574

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K173574. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-09
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Processed digital 2D mammograms from FFDM systems, with images extracted from DICOM files; the packet identifies GE Senographe Essentials and Hologic Selenia Dimension systems and supports CC/MLO pairs or specified single-view inputs.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-09 · FDA K173574: DenSeeMammo

  2. Routing

    Source context, not route validation: The software works in client-server mode: the user computer and server must be on the same local network, the server performs computation and provides the browser-based interface, and processed images are extracted from DICOM files. The FDA packet does not establish a PACS or RIS interface.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-09 · FDA K173574: DenSeeMammo

  3. AI processing

    Source context, not route validation: The exact FDA package describes DenSeeMammo working in client-server mode, with computations made on a server on the same local network as the user computer and a web browser required to display the graphical user interface. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "The software works in a client-server mode and requires that the user computer be on the same local network as the server. Computations are made on the server part of the system that also" … "A web browser is required to display the graphical user interface: to select the patients’ images and to display the assessment". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA K173574: DenSeeMammo

  4. Returned objects

    Source context, not route validation: A BI-RADS breast-density 5th Edition category is produced for each breast and for each patient, with the patient result based on the maximum category of the two breasts; the browser interface can display the assessment and similar images.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-09 · FDA K173574: DenSeeMammo

  5. Viewer/worklist/report

    Unresolved route: A BI-RADS breast-density 5th Edition category is produced for each breast and for each patient, with the patient result based on the maximum category of the two breasts; the browser interface can display the assessment and similar images.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-09 · FDA K173574: DenSeeMammo

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes DenSeeMammo working in client-server mode, with computations made on a server on the same local network as the user computer and a web browser required to display the graphical user interface. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "The software works in a client-server mode and requires that the user computer be on the same local network as the server. Computations are made on the server part of the system that also" … "A web browser is required to display the graphical user interface: to select the patients’ images and to display the assessment". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
The software works in client-server mode: the user computer and server must be on the same local network, the server performs computation and provides the browser-based interface, and processed images are extracted from DICOM files. The FDA packet does not establish a PACS or RIS interface.
  • Exact FDA submission
  • Checked 2026-09-09
Training
The 510(k) summary states that the final assessment of breast density category is made by an MQSA-qualified interpreting physician.
  • Exact FDA submission
  • Checked 2026-10-27

User qualification wording only; the summary specifies no training program or training offering for this device.

Input or output interoperability

DICOM is explicitly referenced in the described input, output, or workflow.

exact submission · checked 2026-09-01

The model card does not establish every supported DICOM object, transfer method, or local interface.

Supported acquisition environment

Scanner manufacturers: GE;Hologic/Lorad

exact submission · checked 2026-09-01

Confirm currently supported software versions, protocols, and site-specific acquisition configurations.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for DenSeeMammo; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-09
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K173574
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Mammography/DBT
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Anatomy
Breast
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2018-06-26
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
24Fields reviewed
9Source classes checked
1Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate record. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission

    No public price or quote for the exact K173574 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-09 - Exact FDA submission

    Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.

  • Installation timeline: Not yet reviewed
  • Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

7 sources - 3 history items

Source ledger

  1. FDA K173574: DenSeeMammo

    U.S. Food and Drug Administration - Published 2018-06-26 - Accessed 2026-09-09

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, deployment

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. DenSeeMammo model card (K173574)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, output, limitations, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K173574

    U.S. Food and Drug Administration - Accessed 2026-09-09

    Scope: postmarketSafety

Research history

  1. K173574 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K260714

MammoScreen® (5)

Therapixel

Authorized purpose: Flags calcifications, masses, asymmetries and architectural distortions on compatible FFDM or DBT screening examinations; management must not be based solely on MammoScreen output.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-06-26
FDA-cleared K253825

Saige-Dx

DeepHealth, Inc.

Authorized purpose: Concurrent detection and characterization support for screening DBT mammography

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-06-15
FDA-cleared K252954

MammoSightAI

Neurocareai, Inc. (Dba Savelife.Ai)

Authorized purpose: Tags screening cases as suspicious or blank to aid worklist prioritization; radiologists must review every examination and it does not mark original images.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-05-04
FDA-cleared K260320

Lunit INSIGHT MMG (v1.1.10)

Lunit, Inc.

Authorized purpose: Lunit INSIGHT MMG v1.1.10 aids physicians in detection, localization and characterization of suspicious breast-cancer areas on female screening mammograms from compatible FFDM systems, viewed after the physician's initial read as an adjunct to complete clinical interpretation.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-04-23

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history